Historique
Rapport
Advisory: Cannabidiol (CBD) - Potential harms, side effects, and unknowns
Auteur(s) :
SAMHSA (Substance Abuse and Mental Health Services Administration)
Année
2023
Page(s) :
11 p.
Langue(s) :
Anglais
Éditeur(s) :
Rockville, MD : SAMHSA
, PEP22-06-04-003
Domaine :
Autres substances / Other substances
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus mots-clés
CANNABIDIOL
;
CANNABINOIDES
;
LEGISLATION
;
EFFET SECONDAIRE
;
VENTE
;
DEFINITION
;
PLANTES
;
MARKETING
;
FACTEUR DE RISQUE
Thésaurus géographique
ETATS-UNIS
Résumé :
This advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. The advisory focuses on the risks and harms of CBD, especially those sold over the counter. This advisory also clarifies common misconceptions about CBD, given its broad availability and marketing for several medical conditions despite limited evidence of efficacy.
It is critical that the general public be made aware of the potential harms associated with CBD use, and parents, in particular, should be advised to not let their children use non-FDA-approved CBD products.
It is critical that the general public be made aware of the potential harms associated with CBD use, and parents, in particular, should be advised to not let their children use non-FDA-approved CBD products.
Affiliation :
USA